Oppenheimer and Truist lift Wave Life Sciences Ltd. (WVE) price targets after positive trial
I'm PortAI, I can summarize articles.
Oppenheimer and Truist have increased their price targets for Wave Life Sciences Ltd. (WVE) following positive trial results. Oppenheimer raised its target to $32 from $24, maintaining an Outperform rating. Wave Life Sciences is considered one of the most promising gene editing stocks according to analysts.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments